Michel Héry Selected Research

Drug Therapy (Chemotherapy)

10/2006

Epirubicin-based chemotherapy as adjuvant treatment for poor prognosis, node-negative breast cancer: 10-year follow-up results of the French Adjuvant Study Group 03 trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michel Héry Research Topics

Disease

2	Breast Neoplasms (Breast Cancer) 10/2006 - 10/2002
1	Asthma (Bronchial Asthma) 07/2007
1	Chronic Renal Insufficiency 01/2007
1	Glomerulonephritis 01/2007
1	Chronic Kidney Failure (Chronic Renal Failure) 01/2007
1	Proteinuria 01/2007
1	Neoplasms (Cancer) 10/2006
1	Neoplasm Metastasis (Metastasis) 10/2002

Drug/Important Bio-Agent (IBA)

1	Methacholine Chloride (Methacholine)FDA Link 07/2007
1	Immunoglobulin A (IgA)IBA 01/2007
1	SolventsIBA 01/2007
1	Epirubicin (Ellence)FDA LinkGeneric 10/2006
1	Estrogen ReceptorsIBA 10/2006
1	Progesterone Receptors (Progesterone Receptor)IBA 10/2006
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2006
1	Fluorouracil (Carac)FDA LinkGeneric 10/2006
1	Dihydrotachysterol (AT 10)IBA 10/2002

Therapy/Procedure

1	Adjuvant Chemotherapy 10/2006
1	Drug Therapy (Chemotherapy) 10/2006
1	Therapeutics 10/2002